A股異動丨愛爾眼科放量大升,或主要系資金交易層面因素所致
愛爾眼科(300015.SZ)盤中一度大升超13%報11.2元,股價創6月19日以來新高,最終收升10.24%報10.87元,成交額放大至近24.57億元,創2023年10月以來新高。有市場分析人士指出,愛爾眼科大升主要系資金交易層面因素——轉融券業務暫停,公司存量轉融券存在較大平倉需求。至於後續怎麼看?該人士指出,Q3起公司高基數季度已過,6月以來屈光需求雖仍有承壓,但價格並未觀察到進一步下降,行業競爭正趨於理性和穩定,公司經營趨勢有望逐季好轉。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.